In the clinic, antibiotic-resistant infections are encountered regularly. These infections sometimes cannot be treated using conventional drugs and according to estimates from 2007, 25.000 people die annually in the EU due to antibiotic-resistant infections. The WHO has recently called upon its member countries to invest in the development of new antimicrobial dugs.
A promising alternative to antibiotics are bacteriophages, viruses that kill bacteria. These viruses could be applied to treat bacterial infections and have been used in clinics in Georgia and Poland for many years. Sadly, clinical trial data on the efficacy and safety of phages in therapy is currently lacking.
Fagenbank is creating a collection of phages against antibiotic-resistant and other dangerous bacteria wants to investigate their safety and efficacy to treat bacterial infections. In collaboration with doctors, scientists, politicians and insurers, the aim is to facilitate phage therapy in the Netherlands and to create awareness on the possibilities and limitations of this therapy.
The Fagenbank is part of the TU Delft and is an initiative of the Brouns lab, which conducts research on phage biology, bacterial resistance, and bacterial defense systems (e.g, CRISPR).
Technical duties are performed by Boris Estrada Bonilla
The Fagenbank is funded by a start-up grant from the TU Delft. Additionally, donations can be made to the Fagenbank through an ongoing crowd funding campaign.
The website will be inaugurated on February 21, 2019. Stay tuned!